Saltar al contenido
Merck

Multiple-dose quazepam kinetics.

Clinical pharmacology and therapeutics (1984-04-01)
M Chung, J M Hilbert, R P Gural, E Radwanski, S Symchowicz, N Zampaglione
RESUMEN

Quazepam, a benzodiazepine hypnotic, was studied in normal subjects to evaluate steady-state kinetics of quazepam and of its major active plasma metabolites, 2-oxoquazepam and N-desalkyl-2-oxoquazepam, after 15 mg once daily by mouth for 14 days. The kinetics of quazepam and 2-oxoquazepam can be best described by a two-compartment open model with first-order absorption/formation kinetics. Quazepam was rapidly absorbed and its two major plasma metabolites appeared very quickly in systemic circulation. The elimination t 1/2s of quazepam, 2-oxoquazepam, and N-desalkyl-2-oxoquazepam were 41, 43, and 75 hr. Steady-state levels were predictable from the kinetic data and were reached by the seventh dose for quazepam and 2-oxoquazepam and by the thirteenth dose for N-desalkyl-2-oxoquazepam. These kinetic profiles may explain the clinical hypnotic effect of quazepam--rapid induction of sleep and long duration of clinical action without appreciable rebound insomnia.

MATERIALES
Referencia del producto
Marca
Descripción del producto

Supelco
Desalkylflurazepam solution, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®